Bosch 2019 / HOPE-3

Study ID(s) and Acronym(s)
HOPE-3 / NCT00468923 / The Heart Outcomes Prevention Evaluation-3
Current Status of Trial
Completed
Study Aim
Primary Prevention
Study Design
RCT
Blinding
Double-blind
Intervention type
Pharmacological
Intervention
Candesartan plus Hydrochlorothiazide//Placebo
Dosage and Duration
Participants without known cardiovascular disease or need for treatment were randomized to candesartan (16 mg) plus hydrochlorothiazide (12.5 mg) or placebo and to rosuvastatin (10 mg) or placebo.
Absolute Number of Participants
2361
Health Status/Diagnosis
Elderly at intermediate cardiovascular risk
Primary outcomes
Cardiovascular death
Other outcomes
Cognitive function
Key Points
"Cognitive assessments were completed by 2,361 participants from 228 centers in 21 countries. Compared with placebo, candesartan/hydrochlorothiazide reduced systolic blood pressure by 6.0 mm Hg, and rosuvastatin reduced low-density lipoprotein cholesterol by 24.8 mg/dL. Participants were followed up for 5.7 years (median), and 1,626 completed both baseline and study-end assessments. Mean participant age was 74 years (SD ±3.5 years); 59% were women; 45% had hypertension; and 24% had ≥12 years of education. The mean difference in change in DSST scores was -0.91 (95% confidence interval [CI] -2.25 to 0.42) for candesartan/hydrochlorothiazide compared with placebo, -0.54 (95% CI -1.88 to 0.80) for rosuvastatin compared with placebo, and -1.43 (95% CI -3.37 to 0.50) for combination therapy vs double placebo. No significant differences were found for other measures. CONCLUSIONS: Long-term blood pressure lowering with candesartan plus hydrochlorothiazide, rosuvastatin, or their combination did not significantly affect cognitive decline in older people." Bosch 2019